| Bioactivity | LSD1/EGFR-IN-1 (compound L-1) is a potent inhibitor of LSD1, EGFRT790M/L858R and EGFRL858R/T790M/C797S, with IC50s of 6.24 and 2.06 and 5.01 μM, respectively. LSD1/EGFR-IN-1 plays an important role in cancer research[1]. |
| CAS | 336171-65-4 |
| Formula | C21H20ClN3O4 |
| Molar Mass | 413.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yu Wei, et al. Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy. Acta Pharmacol Sin. 2025 Jan 3. doi: 10.1038/s41401-024-01439-w. |
LSD1/EGFR-IN-1
CAS: 336171-65-4 F: C21H20ClN3O4 W: 413.85
LSD1/EGFR-IN-1 (compound L-1) is a potent inhibitor of LSD1, EGFRT790M/L858R and EGFRL858R/T790M/C797S, with IC50s of 6.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.